November 13, 2020
Pharmacological Inhibition of Aldose Reductase by AT-001 Prevents Abnormal Cardiac Energy Metabolism and Improves Heart Function in an Animal Model of Diabetic Cardiomyopathy
American Heart Association (AHA) Scientific Sessions 2020
October 26, 2020
Positive Biomarker Efficacy Results from the ACTION-Galactosemia Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Post-Natal Galactitol Reduction is Associated with Normalization of CNS Phenotype in Animal Model of Galactosemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
American Society of Human Genetics (ASHG) 2020 Annual Meeting
September 23, 2020
AT-001: A Next Generation Aldose Reductase Inhibitor with Improved Potency, Selectivity and Specificity Protects from Cellular Damage Associated with Hyperglycaemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Addressing Safety and Specificity with Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
56th Annual Meeting of the European Association for the Study of Diabetes (EASD)
AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Applied Therapeutics Galactosemia Educational Symposium
Presented by Dr. Shoshana Shendelman, PhD & Dr. Riccardo Perfetti, MD, PhD
The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD
Presented by Dr. Francesca Lawson, MD, FAHA
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (poster)
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy
May 25-28, 2019
Beneficial effects of AT-001, an aldose reductase inhibitor, in rodent models of Diabetic Cardiomyopathy
European Society for Cardiology 6th World Congress on Acute Heart Failure
Athens, Greece
October 15-16, 2018
A Novel Investigational Treatment In Preclinical Development For Galactosemia
NORD Rare Summit 2018
Washington, D.C.